Quarterly ResultAug 6, 2026, 07:52 AM
Climb Bio Secures $103.4M Private Placement; Q2 Net Loss $13.5M
AI Summary
Climb Bio, Inc. reported a net loss of $13.5 million for the second quarter of 2026 and $27.2 million for the six months ended June 30, 2026. The company significantly strengthened its financial position by raising $103.4 million through a private placement of common stock and pre-funded warrants. This capital raise increased cash, cash equivalents, and marketable securities to $239.2 million, providing sufficient liquidity for at least the next twelve months.
Key Highlights
- Secured $103.4M from private placement of common stock and pre-funded warrants.
- Cash, cash equivalents, and marketable securities reached $239.2M as of June 30, 2026.
- Liquidity expected to cover operating requirements for at least 12 months.
- Q2 2026 net loss was $13.5M, compared to $8.7M in Q2 2025.
- H1 2026 net loss decreased to $27.2M from $29.4M in H1 2025.
- H1 2026 total operating expenses were $30.6M, down from $33.7M in H1 2025.
- Accumulated deficit grew to $316.9M as of June 30, 2026.
Price Impact
More from CLYM